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Abstract 
Burkholderia cepacia complex (Bcc) is a consortium of at least 20 closely related Gram 
negative species that are a risk factor for cystic fibrosis (CF) patients.  Previously in B. 
pseudomaelli, a hypothetical protein with no known function, was identified to be a novel 
virulence factor and involved in attachment.  In this work, highly conserved homologs in Bcc 
K56-2 and LO6 were examined in multiple in vitro and in vivo models such as attachment to 
eukaryotic cell lines, biofilm attachment and formation, Caenorhabditis	elegans survival model, 
Drosophila melanogaster feeding model, and mouse lung infection.  We found that the deletion 
mutants had impaired attachment and biofilm formation, and significantly lower in vivo survival 
and replication, compared to the wildtype strains. Finally, C. elegans and mice infected with the 
mutants had better survival compared to wildtype infections, supporting the hypothesis that the 
protein surface attachment protein 1, or sap1, is a virulence factor.   
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Chapter 1: Introduction 
1.1 Burkholderia cepacia Complex 
Burkholderia cepacia complex (Bcc) is a consortium of at least 20 closely related Gram 
negative, non-spore forming bacilli species (1).  Species within Bcc have up 78% of their genes 
in common, with genomes ranging from 7 to more than 9 Mbs that are typically divided amongst 
3 chromosomes and a plasmid (2).  They have an average GC content of 67%, and possess 
numerous gene duplications, insertion sequences, and mobile elements (3, 4). This plasticity is 
thought to contribute to their ability utilize a variety of metabolic pathways and thus improve 
their resiliency (5, 6).  Another benefit is the increased mutation rate of the genome when 
stressed, such as in infections (7).  Bcc gets its namesake from the 1950 characterization of B. 
cepacia as a pathogen of onions by W.H. Burkholder, who identified it at the time as 
Pseudomonas cepacia (8).  Further isolates continued to be classified under the genus 
Pseudomonas until 1992 when they were transferred to the genus Burkholderia based on 
molecular factors including 16S rRNA sequencing, DNA-DNA hybridization values, fatty acid 
composition and phenotypic characteristics (9).  This redesignation also suggested that B. 
cepacia was a single type strain, which lasted five years until it was demonstrated using recA 
gene sequencing that there were at least five distinct species, or genomovars, comprising B. 
cepacia (10).  The proposed and accepted solution was to umbrella those genomovars under the 
new coined Burkholderia cepacia complex.   Today there are ten recognized genomovars (I-X) 
which have been given their own speciation, as well as further speciation and subtyping based on 
advances in whole genome sequencing, global transcriptional analysis and past methods such as 
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ribotyping, multilocus enzyme electrophoresis, and pulse field gel electrophoresis (Table 1) (1, 
5).   
While originally identified as a pathogen of plants, Bcc gained notoriety especially for 
infecting immunocompromised individuals and cystic fibrosis (CF) patients. The first reports 
occurred in the 1970s and 1980s, with one coining the “cepacia syndrome” when describing 
patients at a Toronto CF center, being categorized by necrotizing pneumonia, bacteremia, and 
sepsis, along with high levels of morbidity and mortality (12, 13).  Sequencing and molecular 
epidemiological studies of the more virulent Bcc species led to understanding that the pathogen 
can be passed from person, leading to implementation of strict segregation guidelines (14, 15).  
Additionally, treatment with antibiotics was ineffective due to innate antibiotic and antimicrobial 
resistance (16, 17). These epidemic strains are the focal point of understanding the virulence of 
this highly problematic opportunistic human pathogen group. 
 
1.2 Cystic Fibrosis 
Having an autosomal recessive disorder, CF patients are born with mutations within the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes a protein 
responsible for chloride and bicarbonate transport in epithelial cells found in multiple organ 
systems (18, 19).  It affects mostly those of Caucasian/European decent at a rate of 1 in 1000 
births and has over 2000 gene variants divided into six main classes (19).  The most predominant 
mutation known as Phe508del or ∆F508 and prevents CFTR from properly incorporating into 
epithelial cell membranes (19, 20). This is the most common mutation accounting for 66% of CF 
cases worldwide and 90% of CF cases in the USA (19–21).  This deletion leads to impaired 
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mucociliary clearance, increased amounts of mucus, and changes the pH of airway surface liquid 
in the lung (20, 22).  All of these symptoms foster an excellent environment for pathogens, 
making the lung infection the main cause of CF patient mortality (20, 23–25).  Major 
constituents of CF infections are opportunistic pathogens such as Haemophilus influenzae, 
Staphylococcus aureus, and Pseudomonas aeruginosa (18, 26).   Most of these pathogens’ 
virulence can be effectively limited by periodic treatment that reduces the bacterial load in the 
lung (18, 25, 26). However, upon acquisition of Bcc, lung function continues to decline despite 
treatment (18).  Even total lung transplants, currently the closest approximation to a “cure”, 
cannot secure survival, often leading to Bcc-positive patients to be excluded from transplant lists 
(28, 29).  These cases of reinfection are still not totally understood, but it is thought that the 
ability to survive intracellularly and disseminate among different organs contributes to that 
outcome (30–32).  For patients infected with Bcc, 20% will suffer from cepacia syndrome, 
leading rapidly to patient death and if not, Bcc will become a chronic infection by adapting to the 
lung environment for as long as the patient lives (33, 34).  Due to the reduced opportunity and 
effectiveness of treatment for Bcc infections, CF patients depend on a better understanding of 
how Bcc is able to create and maintain disease. 
 
1.3 Virulence Factors Used for Attachment by Bcc 
The diversity and resilience of Bcc leads to the current understanding that there are 
overlapping layers of virulence factors that contribute to disease, especially in regards to 
attachment – a prerequisite for invasion of eukaryotic cells (31, 35, 36). Understanding the 
mechanisms behind these traits is key to developing treatment for both chronic and acute disease 
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(37).  Some are identified as notable factors including cable pili, flagella, autotransporters, outer 
membrane proteins, lipoproteins, exopolysaccharide (EPS) biosynthesis and biofilm formation 
(11, 38–44).  
Cable pili are long multimer structures that have been shown to allow for bacterial interaction 
and grouping (45).  Additionally, when associated with a 22-kDa adhesin, Bcc utilize cytokeratin 
13 as a receptor to bind to eukaryotic cells in the CF lung (45, 46). Outside of motility, flagella 
are another means of Bcc attachment and invasion of host cells (30).  Interestingly, studies show 
that after infection is underway, Bcc can suppress flagella expression if transitioning to a chronic 
infection or if isolated from the blood (33, 47).  This finding makes sense, as Bcc flagella can be 
recognized by Toll-like receptor 5 (TLR5) and triggers an inflammatory signaling cascade in the 
host’s immune response, possibly preventing the dissemination (48).   
Autotransporters are proteins of the type V secretion system that are able to incorporate 
themselves into the bacterial membrane to secrete or act as an effector on the extracellular milieu 
(49).  Recently, the Bcc autotransporter BcaA was found to bind to tumor necrosis factor 
receptor 1 (TNFR1) on lung epithelial cells, as well as provide protection from serum mediated 
death (41, 50).   
EPS production is an important part of Bcc species’ ability to maintain a chronic infection 
(51).  EPS are various long branching polysaccharides that are secreted into the extracellular 
milieu and can confer protection from host mediated defenses while also promoting attachment 
and persistence (52, 53).  One of the more common Bcc EPS is cepacian, which is linked to 
protection from clearance in the lungs as well as a component of the thicker Bcc biofilms (51, 
53).  Biofilms are complex bacterial communities that produce EPS and extracellular DNA 
(eDNA), which protect from host defenses and increase resistance to antibiotics in the CF lung 
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(54, 55). The ability for Bcc to form biofilms is independent of genomovar classification, but 
instead are linked to production of acyl-homoserine lactones (AHLs) and other quorum sensing 
molecules (56).  Interestingly, Bcc is often a co-inhabitant of Pseudomonas aeruginosa biofilms 
in the CF lung, which leads to a “cross-talk” from P. aeruginosa quorum sensing signals and 
contribute to the biofilm even if the Bcc strain forms weak biofilms by itself (57, 58).  For some 
Bcc species, the biofilm maintains close proximity of the bacteria and epithelial cell junctions, 
aiding in Bcc to squeeze through the junctions via paracytosis (59).     
Other genes in Bcc may be involved in attachment and biofilm formation and hypothetical 
proteins found within the genomes should be characterized.  Previously, we identified in 
Burkholderia pseudomallei (Bp) a hypothetical protein involved in attachment and localized to 
the surface of the bacteria.  Furthermore, the mutant strain was completely attenuated after 60 
days in an intranasal mouse infection model (manuscript in preparation). This protein has a 
highly conserved homolog in many Bcc species (two examples of Bcc type strains shown in 
Figure 1), prompting the hypothesis that this protein is a virulence factor for Bcc as well (60).  
 
1.4 Research Aims 
The goal of this work was to test the hypothesis that the hypothetical protein surface 
attachment protein 1 or sap1 (XM57_RS04855 in B. cepacia LO6 and 
BURCENK562V_RS004960 in B. cenocepacia K56-2) is a virulence factor involved in 
attachment.  This was accomplished by deletion mutant construction and complementation, 
followed by utilization of in vitro and in vivo models to determine the extent of involvement of 
sap1 in attachment and pathogenesis.    
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Chapter 2. Materials and Methods 
2.1 Bacterial Strains, Cell Culture and Growth Conditions 
All strains used and generated, as well as plasmids in this study are listed in Table 2 and 3. 
Bcc and E. coli were cultured using Luria-Bertani (LB) medium (Difco) or 1× M9 minimal 
medium supplemented with 20 mM glucose, 500 µM MgSO4, and 25 µM CaCl2 (MG), and 
following additives when appropriate: trimethoprim (100 µg/mL for E. coli, 200 µg/mL for K56-
2, 300 µg/mL for LO6), tetracycline (10 µg/mL for E. coli, 50 µg/mL for K56-2, 150 µg/mL for 
LO6), tellurite (10 µg/mL for E. coli, 125 µg/mL for Bcc) chloramphenicol (20 µg/mL for E. 
coli, 150 µg/mL for Bcc), glyphosate (0.1% v/v for E. coli, 0.4% v/v for Bcc), chlorinated 
phenylalanine (cPhe, 0.1% w/v), and diaminopimelic acid (100 µg/mL).  
Derivatives of E. coli strain EPMax10B (BioRad), E1345 and E1869 were routinely used for 
cloning or plasmid mobilization into Bcc as described previously (61, 62).  
Human lung epithelial cell line A549 and murine macrophage cell line RAW264.7 were 
cultured in DMEM containing 4.5 g/L glucose with 4.0 mM L-glutamine (HyClone).  All 
cultures were supplemented with 10% (v/v) heat-inactivated standard fetal bovine serum (FBS; 
HyClone) and antibiotic/antimycotic solution (100 U/mL penicillin, 100 µg/mL streptomycin, 
and 250 ng/mL amphotericin B; HyClone).  Cells were maintained at 37°C and 5% CO2 in a 
humidified incubator. Cell lines were maintained at 50-80% confluence at which point 
RAW264.7 macrophages were passaged by scraping the cells from the flasks using a cell 
scraper. A549 cells were passaged by first washing with warmed PBS, followed by a 15 min 
detachment incubation with 0.25% trypsin-EDTA (Gibson) at 37°C and 5% CO2 in a humidified 
incubator.  The media-cell suspension was collected, gently pelleted, washed twice with pre-
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warmed DMEM, and distributed to new flasks.  Cell lines were maintained in Corning™ flasks 
and plates with CellBIND™ surfaces. Cell concentrations were determined using the Scepter 
handheld automated cell counter (Millipore). 
 
2.2 General Molecular Techniques 
2.2.1  Oligonucleotides  
Oligonucleotides were synthesized through Integrated DNA Technology and are listed in 
Table 4. All molecular methods and their components utilized were employed as previously 
described (61). 
2.2.2  Reagents  
All restriction enzymes, DNA markers, T4 DNA polymerase, T4 DNA ligase, calf intestinal 
alkaline phosphatase (CIP), deoxynucleoside triphosphates (dNTPs) were purchased from New 
England Biolabs (NEB) and used as recommended by the supplier. Pfu and Taq DNA 
polymerases were purchased from Stratagene. 
2.2.3  Polymerase Chain Reaction (PCR) 
 
PCR was generally performed by initial denaturation at 94oC for 3 min and 30 cycles of 15 s 
at 94oC, 15 s at 50 – 70oC (determined by the melting temperature of primers), and 1 min per kb 
at 72oC, with a final step of 10 min extension at 72oC. Fifteen pmol to 30 pmol of forward and 
reverse primers, 10 ng – 100 ng DNA template and 5 U of Pfu DNA polymerase were used per 
50 µL reaction.  Dimethyl sulfoxide (DMSO) at 2.5 – 10% (v/v) was supplemented to the PCR 
reactions when some of the GC rich chromosomal regions of Bcc chromosome were difficult to 
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amplify.  Additional steps taken to assist with difficult amplification, Taq polymerase was mixed 
with Pfu at a 1:5 ratio when the downstream application of the PCR product was not sensitive to 
the adenine that Taq can add to the end of the PCR product. 
2.2.4  Gel Electrophoresis and DNA Extraction 
 
Various DNA samples can be separated based on their size difference on 1-2% agarose gel 
by running at 110V for 60 min. SYBR® Safe stain was used for the visualization of the DNA 
fragments. DNA bands of desired sizes were excised from agarose gel and DNA was extracted 
by using Zymo Gel Recovery Kit (Zymo Research Corporation) following the manufacturer’s 
protocol. 
2.2.5  Isolation of Bacterial Chromosomal DNA and Plasmid DNA 
 
Three mL of overnight culture was used to isolate E. coli and Bcc chromosomal DNA 
utilizing the phenol-chloroform extraction protocol (63). 
Zyppy Plasmid Miniprep I kit (Zymo Research Corporation) was used for isolation of 
plasmid DNA from E. coli grown overnight by following the supplier’s instruction.  
DNA concentrations were measured using a Thermo Scientific NanoDropTM 1000 
Spectrophotometer according to the manufacturer’s protocol. 
2.2.6  Restriction Enzyme Digestion and Ligation 
 
Restriction enzyme digestions were usually incubated at 37oC for at least 2h. To de-
phosphorylate vectors, CIP was added directly to the digestion mixture followed by 30 min 
incubation at 37oC.  If necessary, gel electrophoresis was used to purify the restriction enzyme 
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digestion mixture to allow subsequent enzyme digests. 
A 10:1 molar ratio of insert DNA fragments to vector DNA was used for ligation. Generally, 
a final volume of 10 µL was used for a ligation reaction with 1 U T4 DNA ligase in 1x ligation 
buffer. The ligation reaction was incubated at 16oC for at least 4 h. Ligation mixtures were 
routinely transformed into various E. coli strains according to the need.  
Electro-competent E. coli cells were prepared as described previously, and chemically 
competent E. coli cells were prepared via the MgCl2/CaCl2 method as described previously (63, 
64). 
 
2.3 General Techniques 
2.3.1  Bacterial Conjugation 
E. coli mobilizable strains E1354 and E2072 were routinely used as donor strains to 
introduce vectors containing oriT into Bcc recipient strains. Helper plasmid pRK2013 was used 
as an alternative to mobilize plasmids into E. coli and Bcc. Briefly, the donor and recipient 
strains were grown up to mid-log phase in LB broth, at which point 0.5 mL of each culture was 
gently mixed in a sterile 1.5 mL microfuge tube and spun down at 7,000× g. The cell pellet was 
gently resuspended in 20 µL of LB broth and spotted on a pre-warmed LB agar plate. After 
overnight growth, the cells were scraped off and washed with 1 mL of 1x M9 salt buffer twice, 
and dilutions were plated on the appropriate selective media.  
2.3.2  Construction of Mutants and Complementation Strains 
Bcc strains K56-2 and LO6 were mutated utilizing pKaKa-OOT-comE-crp for both strains 
(65).  Briefly, pKaKa-OOT-comE-crp was tri-parentally conjugated into each Bcc strain assisted 
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by pRK2013 and selected on MG and appropriate tetracycline concentration. For mutant 
construction, pFRT-Tp-pheS was used as PCR template with primers O3093-3096.  After gel 
electrophoresis and purification, 5µl containing 1 µg of the ~2.2 kb PCR product was co-
incubated with pelleted mid-late log Bcc strains containing pKaka-OOT-comE-crp at room 
temperature for 30 minutes.  The co-incubation mixture was recovered in 4 mL of LB for 4 hours 
shaking at 225 RPM after which the culture was harvested and plated on LB + Tp200 (K56-2) or 
LB +Tp300 (LO6).  Resulting colonies were purified on their respective media, and screened for 
proper deletion via PCR. Once confirmed, the strains were grown in LB to mid-log and saved in 
glycerol at -80°C.  Verified mutants were then tagged using the mini-Tn7-gat-rfp plasmid as 
described (66). Successful transposition was verified with PCR of the four glmS sites and 
fluorescent microscopy. 
Complementation also utilized the mini-Tn7 based integration method (61, 66).  Briefly, Bcc 
genomic DNA was used as template for PCR with respective primers (O3297-O3300) to amplify 
the sap1 gene, as well as introducing KpnI digestion sites on either side to be cloned into mini-
Tn7-gat-gfp linearized by KpnI.  The resulting plasmids, mini-Tn7-gat-gfp-sap1_K56 and mini-
Tn7-gat-gfp-sap1_LO6, were then digested with PstI and XhoI to replace the gat gene with a 
similarly digested pwFRT-PCS12-Telr, in order to differentiate strains in competition assays.  
Additionally, a Cmr cassette was cloned in by BspHI and BglII digestion of pPS854-FRT-Cmr 
and the appropriate complementation vector.  Restriction digest verified the plasmids’ size and 
orientations.  Genomic integration of the complementation vectors mini-Tn7-Cm-tel-gfp-
sap1_K56 and mini-Tn7-Cm-tel-gfp-sap1_LO6 was done as previously described and verified 
by PCR and florescent microscopy (66).   
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2.4  Growth Characterization of Mutants and Complementation Strains 
Wildtype, mutant, and complemented strains were grown to stationary phase, subcultured 
1:200 into 250 mL of LB in a 500 mL flask and grown at 37°C and 225 RPM. Aliquots of 250 
µL were pulled at designated times, added to 750 µL ddH20 in cuvettes, and absorbance was read 
via spectrophotometer at 630 nm.   
 
2.5  Attachment Assays 
The attachment assay was carried out by dilution of bacterial strains in PBS and plated on 
LB.  Colonies were counted to determine the number of CFU used to initiate the infection and 
calculate attachment efficiencies. The dilutions were used to infect the cell cultures in 24-well 
CellBIND plates at an MOI of 10:1. After 30 minutes, the bacteria-containing medium was 
removed and the monolayers were washed 3 times with pre-warmed PBS. Monolayers were 
lysed with 0.2% Triton-X100 in PBS, diluted, plated onto LB and incubated at 37°C for 48 h. 
Colonies were enumerated and attachment efficiency was determined by dividing the attached 
number by the initial number of bacteria. The experiment was carried out in triplicate and the 
numbers represent the average of all three replicates with the error bars representing the SEM. 
The unpaired student t-test was used to determine the significance of attachment efficiencies 
between the wildtype, mutants, and complements. 
 
2.6  Biofilm Crystal Violet Assay 
Quantification of biofilm production was tested as previously described with modifications 
(67, 68).  Briefly, bacterial strains were grown to late log, subcultured at 1:200, and 125 µL 
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dispensed into Costar SeroclusterTM 96-well microtiter plates (Corning) with each strain being 
replicated ten times.   Uninoculated media served as a negative control. The outside perimeter of 
the 96-well plates was filled with ddH2O to minimize evaporation from wells. After 18 hours 
(the time of maximum biofilm production based on unpublished observations), wells were rinsed 
with ddH2O and patted dry.  At this point, half of the wells were filled with 150 µL of 1% (w/v) 
crystal violet for 15 minutes, rinsed, and let air dry.  The other wells were filled with 150 µL of 
0.1% (w/v) SDS resuspension mixture and mixed via repeated pipetting and scraping of the 
sides.  The resulting resuspensions were then serially diluted and plated on LB to enumerate 
CFUs.  The crystal violet stained wells were solubilized with 200 µL of a modified biofilm 
dissolving solution of 80% ethanol + 10% SDS (w/v), with 150 µL transferred to a flat-bottomed 
96-well microtiter plate and read for absorbance at 550 nm (69).  The student t-test was used to 
determine the significance of differences in biomass and CFUs between the wildtype, mutants, 
and complements. 
 
2.7  Caenorhabditis elegans Survival Studies 
Each bacterial strain was plated on three plates with nematode growth media (NGM) and 
allowed to grow as lawns for 36 hours; fifteen L4 age-synchronized Caenorhabditis elegans (Ce) 
were added to each plate for a total of 45 worms for each Bcc strain (70, 71).  E. coli OP50 was 
used as a food source as well as a negative control. Worms were observed daily and deaths were 
recorded. The experiment was conducted twice with comparable results.   
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2.8  Drosophila melanogaster in vivo Competition Study 
Flies studies were preformed as described previously with modifications (72).  Briefly, 
wildtype Oregon R flies were maintained on standard cornmeal sucrose medium.  Bacterial 
strains were washed in a 5% sucrose + PBS solution, and adjusted to a final 1:1 ratio totaling 
~2.5×1010 CFU/mL, of which 150 µL was added to Whatman filters atop 5 mL of 5% sucrose 
agar in vials and allowed to dry at room temperature for 30 minutes.  Twelve 1-3 day old male 
flies were starved for 3 hours and added to each vial, with three vials for a total of 36 flies used 
per Bcc strain combination.  As a control, the mixtures were also plated on 5% sucrose agar 
without flies to monitor the ratio over time. At two and four days post-inoculation, three flies 
from each vial were taken for CFU enumeration, with each vial’s flies being treated separately. 
Serial dilutions of the fly homogenate were plated onto LB (CFUtotal) or LB with 
chloramphenicol and tellurite (CFUcomplement).  CFUmutant was determined from the difference of 
CFUtotal and CFUcomplement the ratio of which to yields the in vivo CI (CFUmutant/CFUcomplement). 
 
2.9  Imaging of the D. melanogaster Crop 
Additional flies from the above CI experiments were sacrificed; the crops and gastrointestinal 
tract (GI) were carefully removed under a dissection microscope and cured in ProLong Gold 
Antifade reagent (Invitrogen).  A cover slip was placed over the organs and pressed flat to 
remove air bubbles, and sealed with clear nail polish applied along the edges.  After letting cure 
while covered for 30 minutes, the slides were imaged using a Zeiss Observer D1 with AxioCam 
MRc5 and accompanying Axiovision 4.9.1 software. 
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2.10  Animal Studies 
Frozen aliquots of the strains were plated to determine accurate CFUs. Bacteria used for 
inoculations were washed in PBS, diluted to the desired concentration, and plated at the start of 
the study to accurately determine the number of CFUs used.  Six-week-old female BALB/c mice 
were purchased from Jackson Laboratories.  Before challenge, the mice were anesthetized by 
intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine. For the CI studies, 40 µl 
of the 1:1 mutant/complement (~7×107 CFU/mouse) strain mixture was inoculated 
intratracheally using the BioLITE Intubation System (Braintree Scientific), with PBS used as a 
control.  Five mice were used per group.  The same 1:1 mixture was also plated for comparative 
CFU changes as a further control.  After 3 or 5 days, mice were humanely euthanized after which 
their lungs were harvested and homogenized in 5 mL PBS.  Serial dilutions of the homogenate 
were plated onto LB (CFUtotal) or LB with chloramphenicol and tellurite (CFUcomplement).  
CFUmutant was determined from the difference of CFUtotal and CFUcomplement the ratio of which to 
yields the in vivo CI (CFUmutant/CFUcomplement) (73).  
For survival studies, mice were similarly inoculated intratracheally with ~3×108 CFU/mouse 
with five mice used per strain.  After 10 days, surviving mice were humanely sacrificed and their 
lungs, livers, and spleens were homogenized in 5 mL PBS for serial dilution and CFU 
enumeration.   
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Chapter 3: Characteristics of in vitro and in vivo Virulence Assays  
3.1  Introduction 
Bcc as an opportunistic pathogen is troubling due to the morbidity and mortality rate 
associated with the infection in CF patients, due to the lack of effective treatments (3, 74).  One 
of the strategies in dealing with Bcc is sequestration of CF patients from one another, in an effort 
to curb the nosocomial aspect of Bcc infection and is not actually a treatment for patients 
infected with Bcc (1).  Furthermore, Bcc maintains a multitude of virulence factors, as well as an 
ability to mutate the genome when present with a stressful environment only increases resiliency 
(4, 5).  Additionally, the CF environment itself does not lend to easy access to the bacteria for 
removal or killing via host factors and antibiotics (24, 75).  To compound the issue, Bcc is able 
to vacate the extracellular milieu and invade host epithelial cells, as well as prevent degradation 
within host phagocytes (30, 35, 76).  Some of the genes involved in these processes lie within a 
significant Bcc genomic profile, hypothetical proteins, and provide an opportunity to understand 
some of the unique quirks of this pathogenic group (2, 47, 77, 78). 
The Bp sap1 homolog has been shown to be involved in attachment and virulence while 
sharing high homology and identity with Bcc sap1, which lends high confidence that some 
properties will also be conserved as a virulence factor (Figure 1A).  However, due to the 
hypothetical nature of the protein, a suite of assays were used to identify multiple aspects of 
potential virulence.  Here, we examined the Bcc hypothetical protein sap1 to determine the 
extent of its involvement in attachment.   
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3.2  Results 
3.2.1  K56-2 and LO6 Share Similar sap1 Homology and Genomic Organization  
The strains K56-2 and LO6 were used due to having sequenced genomes, as well as success 
using the mutagenesis protocols.  Additionally they represent multiple genomovars and distinct 
lineages; the K56-2 strain related to an epidemic isolate ET-12 that coursed through CF wards in 
Canada, the United Kingdom, and Europe (38, 79).  LO6 is a clinical isolate from Thailand that 
was recently sequenced and is similar to another Bcc species, B. dolosa (60, 80, 81).  At the 
chromosomal level, 5kb upstream and downstream of their respective sap1 homologs shares 
90% identity within 84% of that region in question (Figure 1B).   
3.2.2  Bacterial attachment to eukaryotic cells involves sap1.   
To determine if the Bcc sap1 homolog was involved in attachment, mutants were 
constructed using the lambda-red recombineering system (65) and complemented using the mini-
Tn7 based integration system (61, 66). To ensure that any observed differences between the 
strains were only due to the absence or presence of a functional sap1 gene, the strains’ growth 
kinetics were observed.  The strains showed no significant difference in the growth rates between 
the mutants, complements, and wildtype (Figure 2). These strains were used in attachment assays 
in two different eukaryotic cells lines: A549 human lung epithelial cells and RAW264.7 murine 
macrophages (Figure 3). Of all combinations, K56-2 strains saw the highest attachment to A549 
cells, yet the mutant displayed an 8-fold decrease in attachment (p=0.0165) (Figure 3A).  That 
mutant also experienced nearly a 5-fold decrease in attachment to murine macrophages 
(p=0.028) (Figure 3B). For LO6 strains, the mutant exhibited a 3-fold attachment deficiency in 
A549 cultures (p=0.0026) (Figure 3C), while over a 60-fold decrease in attachment to 
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RAW264.7 cells (p=0.0106) (Figure 3D), the largest defect overall.  Wildtype strains showed no 
significant difference from the complemented strains for either species. These data suggest that 
sap1 is involved in attachment for Bcc strains K56-2 and LO6, and that the chromosomally 
located complement restores the defect of the mutants seen in this model.   
3.2.3 sap1 Effects Biofilm Formation in vitro  
Biofilm formation is a virulence factor especially for CF lung infections due to up-regulation 
of biofilm related genes (56) as well as the transition of clinical CF isolates to a mucoid 
phenotype over time (82).  Given the involvement of sap1 in attaching to eukaryotic cells, we 
also sought to assay if the attachment was utilized for attachment to solid surfaces and biofilm 
formation in vitro and as it pertains to virulence in the well-established Ce model (38, 83, 84). 
Bacterial strains were grown to late log, subcultured and dispensed into 96-well plates for the 
crystal violet biomass assay (Figure 4A, 4D), and determination of CFUs within the biomass 
attached to the wells’ walls (Figure 4B, 4E). Generally, LO6 wildtype and complement strains 
produced nearly a 10-fold increase in biomass when compared to respective K56-2 strains, yet 
the LO6 sap1 mutant displayed nearly the same level of biomass as its K56-2 counterpart (Figure 
4A, 4D). Interestingly, the CFUs recovered from the K56-2 sap1 mutant had nearly an 8-fold 
decrease (p=0.1741), considering there was only about a 20% decrease in biofilm biomass 
(p=0.0007) (Figure 4A, 4B).  The LO6 sap1 mutant, while producing a much more robust 
biofilm, lost over 46-fold CFUs and had a 10-fold loss in biofilm biomass (p<0.0001; p=0.0103) 
(Figure 4D, 4E).  These decreases in the LO6 sap1 mutant point to sap1 playing a significant 
complementary role in LO6 biofilm formation.   
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3.2.4 Virulence of Biofilm Production is Influenced by sap1 
To determine the virulent effects of biofilm formation with and without sap1, strains were 
assayed by determining the survival rate of Ce when allowed to graze on the respective bacteria.  
The experiment was conducted twice with similar results (data for one experiment shown, n=45).  
The K56-2 wildtype and complemented strains saw longer survival than their LO6 counterparts; 
the LO6 strains had a markedly shorter survival curve with total death occurring in nearly half 
the time (Figure 4C, 4F).  Both mutant strains had similar survival curves, with total death 
occurring near the 200-hour mark. When comparing the biofilm in vitro data to the Ce survival 
curves, the Ce worms grazing on poor biofilm producers experienced longer survival, and the 
strains with strong biofilm formation led to shorter Ce survival curves.   
3.2.5  D. melanogaster Model Shows a Decrease in Mutant Competitiveness in vivo 
The strains were also used in the fruit fly feeding model, which has been shown to be useful in 
determining in vivo bacterial fitness, a surrogate model for internal in vivo biofilm formation, and 
a means to corroborate the Ce data in another well-established invertebrate model (72, 85, 86).  
At two and four days post-inoculation, flies were taken to enumerate bacterial loads while 
additional flies were used for fluorescent imaging of the crop.  CFU enumeration of each strain 
allowed for determination of the Competitive Index (CI), a metric to compare the fitness of the 
mutant against the complement, as a ratio of their respective CFUs. When CI < 1, the mutant is 
less competitive than its complement strain when grown together in that environment; the 
smaller the number, the less competitive the mutant strain. While the CI of the inoculum control 
did not show a change over time, the CI of K56-2 stains showed that the complement was able to 
significantly outcompete the mutant three-fold at day 2 (p=0.0007), and maintained that 
advantage to day 4 (p=0.0008) (Figure 5A).  LO6 strains had a similar result, with a three-fold 
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advantage at day 2 (p=0.0007), and nearly doubling that advantage on day 4 (p<0.0001) (Figure 
5B).  Overall, the mutants showed a marked disadvantage in their ability to compete with the 
complement when adapting to the environment within the fly.  Representative fluorescent images 
corroborate this, with hardly any RFP-tagged mutants being visible. The autofluorescence of the 
crop can be seen in the background, with the tagged bacteria seen as points of fluorescence  
scattered throughout the crop. 
 
3.2.6 Mouse Model of Bcc Infection Shows a Decreased Fitness and Lethality of the sap1 
Mutant 
The importance of sap1 was further investigated in the more complex mouse lung. BALB/c 
mice were inoculated via intratracheal intubation to assay the CI of mutant and complement, as 
well as monitor survival at higher doses of wildtype, mutant and complement. Based on pilot 
studies to determine the proper infectious dose and time window of infection, K56-2 was not 
able to colonize the BALB/c lungs, leading to LO6 exclusively being used for this animal study.  
After inoculation with an equal ratio of mutant to complement totaling ~7×107 CFU/mouse, the 
CI at 3 dpi showed a significant 5-fold decrease in the fitness of the mutant (p<0.0001), and 
continuing to decrease to nearly a 10-fold difference at 5 dpi (p<0.0001) (Figure 6A). At day 3, 
the bacterial load of complements recovered was above the inoculum, which indicated that the 
complement was able to replicate and outcompete the mutant when colonizing the lung 
environment. 
Survival studies were also conducted with an inoculum of ~3×108 CFU/mouse.  The mice 
inoculated with the sap1 mutant (n=4) experienced 75% survival at 10 dpi, compared to 20% and 
40% of the wildtype (n=5) and complement (n=5), respectively (Figure 6B).  Lungs, livers, and 
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spleens of the surviving mice were harvested to determine bacterial loads (Figure 7).  
Interestingly, all organs were infected except for the liver from one ∆sap1-infected mouse, which 
had no detectable bacteria (Figure 7B).  The lungs from the wildtype and complement infected 
mice retained a bacterial load that was above or comparable to the inoculum.  This indicates LO6 
was able to replicate and persist in the lung, while also disseminating to other organs, while the 
sap1 mutant exhibited significant defects in ability to colonize and disseminate 
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Chapter 4: Discussion 
In this work, we provide evidence of the hypothetical Bcc protein sap1 as a virulence factor 
based on its involvement in attachment and pathogenesis.  Characterization of sap1 up to this 
point was lacking: a hypothetical protein containing only domains of unknown function that has 
limited homology outside the genus.  Based on the fact that there are multiple ways for Bcc to 
present virulence, a variety of assays were utilized.  Since the sap1 homolog in Bp shared a high 
identity and was identified to be involved in attachment, the first step was to determine if the Bcc 
sap1 could attach to eukaryotic cells.   
LO6 wildtype and sap1 complement exhibited similar attachment efficiencies in both 
epithelial and phagocytic cell lines.  This finding was comparable to the K56-2 wildtype and 
complement strains’ attachment ability to RAW264.7. In contrast, both mutant strains 
experienced decreased attachment efficiency to the epithelial and macrophages eukaryotic cells.  
Looking at the defect of the mutant strains’ ability to attach, there was not a consistently better 
cell type for attachment: LO6 saw the largest defect on RAW264.7 cells while the K56-2 
mutant’s largest defect was attaching to A549s.  This observation does not provide evidence for a 
specific target of Sap1 protein to either A549 or RAW264.7 cells, but does show an involvement 
in the attachment process.  The fact that Bcc attaches to human and mouse cell lines underscores 
the importance of elucidating the role sap1 plays in pathogenesis. 
While K56-2 strains exhibited nearly double the attachment efficiency in the A549 cells, 
K56-2 displayed a lower pathogenicity in the Ce kill curves compared to LO6.  K56-2 was also 
unable to replicate and colonize the mouse lung. As for the biofilm assay, the low K56-2 biofilm 
production is not entirely unexpected, as our lab’s previous work has used LO6 in biofilms 
studies specifically over K56-2 due to its higher ability in forming biofilm in the drip flow 
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model.  This robustness was not uniform, as the LO6 mutant could only produce biomass similar 
to all three K56-2 strains and CFUs recovered – the K56-2 mutant did not exhibit a significant 
difference in bacterial load within the biofilm compared to the wildtype (p=0.1741).  
Surprisingly, the LO6 wildtype and complements were able to harbor nearly 46-fold more 
bacteria in roughly 10-fold the biomass.  This high cell density could have an effect on the 
amount of quorum sensing molecules present and the factors they regulate, or any contact 
dependent virulence factors (19, 20, 27).  Taken together, these factors may contribute to the 
LO6 strains’ increased morbidity in the nematode model and maintain an infection in the 
BALB/c model.   
Compared to K56-2, LO6 did not have the same deficiencies in maintaining an infection in 
the mouse model, as the lungs of the surviving mice contained a bacterial load at or slightly 
higher than the inoculum of wildtype and the complement.  In this study there are no other 
factors potentially masking an attachment defect in the sap1 mutant, since there was no use of 
agar beads, mucoid strains, or co-infections with other pathogens.  These are often used to mimic 
various forms of chronic infections which was outside the objective of these studies (11, 57).  In 
this work, the sap1 mutant was still able to maintain a presence in the lung after 10 days, 
pointing to other virulence factors contributing to infection.  Due to the opportunistic nature of 
Bcc, it is probable that the virulence factors establishing infection are an amalgamation of factors 
to exploit the weakness of the host, and may require a shift in environment to express those 
factors, such as changes from the upper to lower respiratory track (87, 88).  Considering that the 
Bcc genome is known to increase in mutation rate when under stress, it would be interesting to 
see a comparative analysis of the recovered bacteria from the lungs, liver and spleen and 
compare it to the inoculum (4, 47, 89).   
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Overall, the data herein strengthens the hypothesis that sap1 is involved in attachment 
and can be described as a virulence factor.  Its role in pathogenesis can be hypothesized to be one 
of many tools Bcc uses to entrench in the CF lung by interacting with the sputum found in the 
CF lung, or adhesion to the lung epithelial cells.  The close proximity to the already damaged 
lung epithelial cells might then draw the attention of various host immune system cells. If those 
host cells do recognized the pathogen, Bcc could be phagocytized and therefore protected from 
the innate immune system, while being shuttled to the spleen, liver and/or lymph nodes. To 
better understand this interplay, future research should focus on targeting the ligand sap1 
interacts with, resolving the protein’s structure, and determining if it is immunoprotective for 
treatment and potential vaccine development.  
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Tables 
 
Table 1 Bcc genomovars and first descriptors  
Species Genomovar Reference 
B. cepacia I (10) 
B. multivorans II (10) 
B. cenocepacia III (10, 90) 
B. stabilis IV (91) 
B. vietnamiensis V (10) 
B. dolsa VI (80) 
B. ambifaria VII (92) 
B. anthina VIII (93) 
B. pyrrocinia IX (93) 
B. ubonensis X (81) 
B. latens –   (94) 
B. diffusa – (94) 
B. arboris – (94) 
B. seminalis – (94) 
B. metallica – (94) 
B. contaminans – (95) 
B. lata – (95) 
B. pseudomultivorans – (96) 
B. stagnalis – (97) 
B. territorii – (97) 
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Table 2. Bacterial strains used in this study 
Strain Lab ID Genotype/Description Reference or source 
Bcc    
B. cepacia LO6 P754 Prototroph; cystic fibrosis isolate P. Sokol 
LO6 ∆sap1 E3691 ∆sap1:: FRT-Tpr-pheS/attTn7::miniTn7-gat-rfp This work 
LO6 ∆sap1/comp E3695 ∆sap1:: FRT-Tpr-pheS/attTn7::miniTn7-Cm-
tel-gfp-sap1_LO6 
This work 
B. cenocepacia 
K56-2 
E1554 Prototroph; cystic fibrosis isolate P. Sokol  
K56-2 ∆sap1 E3237 ∆sap1:: FRT-Tpr-pheS/ attTn7::miniTn7-gat-
rfp 
This work 
K56-2 ∆sap1/comp E3693 ∆sap1:: FRT-Tpr-pheS/attTn7::miniTn7-Cm-
tel-gfp-sap1_K56 
This work 
E. coli    
DH5α E0272 F− φ80dlacZΔM15 Δ(lacZYA‐argF)U169 
endA1 recA1 hsdR17(rK − mK +) supE44 thi‐1 
ΔgyrA96 relA1  
Lab collection 
EPMax10B-pir116 
∆asd ∆trp::Gmr 
mob-Kanr 
E1354 Kanr, Gmr,  F- λ- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80dlacZ ΔM15 ΔlacX74 deoR recA1 endA1 
araD139 Δ(ara, leu)7697 galU galKrpsL nupG 
Tn-pir116-FRT2 ∆asd::wFRT  ∆trp::Gmr-FRT5 
mob[recA::RP4-2 Tc::Mu-Kanr] 
Available lab strain 
  
EPMax10B-lacIq 
pir 
E1869 F- λ- mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZ 
ΔM15 ΔlacX74 deoR recA1 endA1 araD139 
Δ(ara, leu)7697 galU galKrpsL nupG lacIq-
FRT8 pir-FRT4 
Available lab strain 
  
EPMax10B-
∆dapA::Gmr-lacIq-
pir leu+ mob-Kanr 
E2072 F- λ- mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZ 
ΔM15 ΔlacX74 deoR recA1 endA1  galU 
galKrpsL nupG ∆dapA:: lacIq-FRT8 pir-Gmr 
leu+ mob[recA::RP4-2 Tc::Mu-Kanr] 
Available lab strain 
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Table 3. Plasmids used in this study. 
Plasmids Lab ID Relevant properties Reference  
pRK2013 E0272 Kanr, helper plasmid encoding conjugative proteins (98) 
pPS854-FRT-Cmr E0855 Apr; Cmr; plasmid with Cmr-FRT-cassette  
pwFRT-PCS12-Telr E1584 Telr;PCS12-Telr cassette flanked by wildtype FRT 
sequences 
(64) 
mini-Tn7-gat-gfp E2462 GSr, mini-Tn7-gat harboring gfp (62) 
mini-Tn7-gat-rfp E2326 GSr, mini-Tn7-gat harboring rfp (62) 
mini-Tn7-Cm-tel-
gfp-sap1_K56  
E3697 Cmr; Telr; mini-Tn7 harboring gfp and K56 sap1 This work 
mini-Tn7-Cm-tel-
gfp-sap1_LO6 
E3699 Cmr; Telr; mini-Tn7 harboring gfp and LO6 sap1 This work 
pTNS3-asdEc E2237 Suicidal helper plasmid containing E. coli asd and 
transposase for the Tn7 site-specific transposition 
system 
(61) 
pKaka-OOT-comE-
crp  
E3217 Tetr; broad-host-range λ-red helper plasmid based on 
Tet resistance that also confers DNA uptake 
In 
preparation 
pFRT-Tpr-pheS E2964 Tpr, Apr, FRT1 flanked Tpr-pheS cassette  (64) 
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Table 4. Primers used in this study 
Primer number and name Sequence 
876; TN7L 5'-ATTAGCTTACGACGCTACACCC-3' 
3093; V_C0817 pheS-gat dw 5'-
GATCCACAGCGCAACGGCCCGGCATGCGCCGGGCC
GTGATCGGTTCAGCTGGCACGACAG-3' 
3094; V_C0817 pheS-gat up 5'-
AAACACATAGCTAACCCAGCCTGGTGCCCGCAAGC
CTGGAGACAGGGCGATTAAGTTGGG-3' 
3095; V_C0817 pheS-M13 dw END 5'-TGCGCGATCCACAGC-3' 
3096; V_C0817 pheS-gat up END 5'-TCACCTTTAAACACATAGCTAAC-3' 
3097; V_C0817 pheS-gat dw screen 5'-GCATTCGGTTCGGTCGG-3' 
3098; V_C0817 pheS-gat up screen 5'-TGTGCTTGCTATCGTTTACCG-3' 
3099; glmS1 Bc K56-2 5’-GTGTGAAACCACTTCGTCTTG-3’ 
3100; glmS2 Bc K56-2 5’-GAAGATCGTGCTCGGCGAAATG-3’ 
3101; glmS3 Bc K56-2 5’-TTCCTGCGTTCGGTGCCAGTCG-3’ 
3102; glmS4 Bc K56-2 5’-CCGAGCTGCTGAAGAACACC-3’ 
3166; BamHI V_C0817 miniTn7 5'-TATATGGATCCGCGGGAATGGACG-3' 
3167; PstI V_C0817 miniTn7 5'-ATATCTGCAGTGGAATCGTTTCGGATG-3' 
3169; L06 PstI V_C0817 miniTn7 5'-ATATCTGCAGCGATAAATTCATATCGTTTCGGC-3' 
3170; L06 BamHI V_C0817 miniTn7 5'-TATATGGATCCGCGCGTTACTGCTTGAT-3' 
3214; HindIII V_C0817 mT7gRFP 5'-ATATAAGCTTGGAATCGTTTCGGATG-3' 
3215; SpeI V_C0817 mT7gRFP 5'-TATATACTAGTCGCGGGAATGGACG-3' 
3216; LO6 HindIII V_C0817 mT7gRFP 5'-ATATAAGCTTCGATAAATTCATATCGTTTCGGC-3' 
3217; LO6 SpeI V_C0817 mT7gRFP 5'-TATATACTAGTCGCGCGTTACTGCTTGAT-3' 
3297; KpnI V_C0817 dn 5'-TATATGGTACCGCGGGAATGGACG-3' 
3298; KpnI V_C0817 up 5'-ATATGGTACCTGGAATCGTTTCGGATG-3' 
3299; L06 KpnI V_C0817 dn 5'-TATATGGTACCGCGCGTTACTGCTTG-3' 
3300; L06 KpnI V_C0817 up 5'-ATATGGTACCGATAAATTCATATCGTTTCGGC-3' 
3499; LO6 glmS1 5'-GGTACCGACGTCGACAAGC-3' 
3500; LO6 glmS2 5'-CGACAAGCCGAGGAATCTGG-3' 
3501; LO6 glmS3 5'-GCTGCTCGCGTATCACACC-3' 
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Figures 
 
Figure 1.  Alignment of sap1 amino acid sequence and surrounding DNA sequence. (A) 
Alignment of sap1 from Bp K96243, B. cenocepacia K56-2 and B. cepacia LO6 using CLC 
Sequence Viewer 7. – denotes a gap; . denotes conservation; mismatches are highlighted in red. 
(B) Syntany map of 5 kb up- and down-stream of the K56-2 and LO6 sap1 using Artemis 
webACT. Identical regions are indicated in red, non-identical regions in white, and blue indicates 
a region that is inverted in the two strains.   
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Figure 2. Growth curves of Bcc K56-2 and LO6 strains. No significant differences were 
observed among the various K56-2 strains or LO6 strains over 48 hours. 
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Figure 3.  sap1 involved in attachment to eukaryotic cells.  Wildtype, mutant, and 
complemented strains’ CFU recovered divided by the inoculum amount from attachment assays 
done in triplicate: (A and B) Bc K56-2 and (C and D) Bc LO6 exposed to A549 human epithelial 
cells and RAW264.7 mouse macrophages.  Error bars signify SEM; * p<0.05, ** p<0.005, as 
determined by unpaired student t-test. Wildtype=WT. 
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Figure 4.  Biofilm production and C. elegans survival is influenced by sap1.  Biofilm 
production and CFUs within the biofilm for (A, B) K56-2 strains or (D, E) LO6 strains. Error 
bars signify SEM; * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001, as determined by 
unpaired t-test. Effects of (C) K56-2 strains or (F) LO6 on C. elegans grazing on the wildtype, 
sap1 mutant, complement, or Ec strains; 45 worms per strain were used.  Wildtype=WT. 
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Figure 5.  Comparative fitness in the D. melanogaster feeding model.  CI of (A) K56-2 or (B) 
LO6 strains after 2 or 4 days of either exposure to grazing flies or in vitro control with no flies.  
Each dot is the CI of a set of 3 flies from one vial, with the geometric mean of the triplicate listed 
above.  Representative images from each strain as ∆sap1 (RFP), complement (GFP) and merged 
channels are listed below; carots indicate bacteria. *** p<0.0005, **** p<0.0001.  
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Figure 6. Comparative fitness and survival curve of mice groups.  (A) CI from mouse lungs 
at 3 and 5 dpi, as well as the initial in vitro inoculum, of  ~7×107 CFU/mouse at a 1:1 mutant to 
complement ratio inoculated via intratracheal intubation. Average CIs are listed at the top.  **** 
p<0.0001 as determined by t-test. (B) Survival curve of LO6 wildtype (n=4), ∆sap1 mutant 
(n=5), the complement (n=5) and PBS control (n=4).  
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Figure 7. Bacterial loads of organs in surviving mice. Mice to survive to the end of the study 
had their (A) lungs, (B) livers, and (C) spleens harvested to determine CFUs.   
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